BS-001 is under clinical development by Wuhan Binhui Biopharmaceutical and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BS-001 overview
OH-2 is under development for the treatment of head and neck cancer, liver cancer, hepatocellular carcinoma, lung cancer, lymphoma, non muscle invasive bladder cancer, advanced bladder carcinoma, breast cancer, gastrointestinal cancer, soft tissue sarcoma, metastatic colorectal cancer, cutaneous squamous cell carcinoma, muscle invasive bladder cancer, recurrent central nervous system tumors including but not limited to anaplastic astrocytoma, esophageal cancer, anaplastic oligoastrocytoma, glioblastoma, anaplastic ependymoma, medulloblastoma, malignant meningioma, metastatic biliary tract cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, ampullary carcinoma and melanoma. The therapeutic candidate is a recombinant oncolytic herpes simplex virus type 2 (oHSV-2). It is administered through intratumoral route.
It was also under development for the treatment of colon cancer, metastatic pancreatic cancer.
Wuhan Binhui Biopharmaceutical overview
Wuhan Binhui Biopharmaceutical (Binhui) is a biotechnology company, that provides innovative products and services in the field of cancer gene and immunotherapy, committing to improving anti-tumor and cancer drugs. Binhui is headquartered in China.
For a complete picture of BS-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
